ArticleMicrobiology spectrum2025
Development and efficacy of a novel mRNA cocktail for the delivery of African swine fever virus antigens and induction of immune responses.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Identification and Characterization of a Novel Linear B-Cell Epitope Within the ASFV pB602L Protein for Serological Diagnosis.Microorganisms · 2026Article
- Fusion with immunoglobulin Fc fragment enhances the immunogenicity of the African swine fever virus p30/p54 fusion protein.Applied microbiology and biotechnology · 2026Article
- Current Insights into the Epidemiology and Transmission Dynamics of African Swine Fever Virus and Future Control Perspectives.Pathogens (Basel, Switzerland) · 2026Review
- Novel B cell epitopes mapping in pD205R protein of African swine fever virus using monoclonal antibodies.BMC veterinary research · 2026Article
- African Swine Fever: Vaccine Advancement and Major Gaps.Microorganisms · 2026Review
- Recombinant vaccinia vectored ASFV vaccine enhances swine survival against genotype II challenge.NPJ vaccines · 2026Article
- Implications for safety:Frontiers in microbiology · 2026Article
- Antibody-Dependent Cellular Cytotoxicity Elicited by the Antibodies Against the E120R Protein of African Swine Fever Virus.Vaccines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
African swine fever (ASF) is a highly lethal infectious disease affecting pigs. Although several vaccine formulations have been developed to protect from ASF virus (ASFV) infection, none have yet provided complete protection without side effects or the risk of progressing to chronic infection. mRNA vaccines offer unparalleled advantages in terms of safety and ability to induce immune responses. In this study, we designed six mRNA vaccines encoding key antigenic proteins of ASFV- B602L, CD2V, EP153R, P30, P54, and P72 and combined them into an mRNA cocktail for vaccination in mice and pigs. Our findings suggest that the mRNA cocktail is capable of provoking robust multivalent humoral and cellular immune responses while maintaining a favorable safety profile. Thus, it may serve as a potential approach for controlling ASF transmission, contributing to the ongoing efforts to develop effective and safe ASFV vaccines. The administration of the mRNA cocktail induced both humoral and cellular immune responses in mice and pigs, suggesting a potential for future ASFV vaccine development.IMPORTANCEThis study explores an mRNA vaccine encoding six critical African swine fever virus (ASFV) antigens (B602L, CD2V, EP153R, P30, P54, P72), demonstrating its ability to induce robust humoral and cellular immune responses in both mice and pigs. This innovative approach serves as a significant advancement in ASFV vaccine development by addressing safety and efficacy concerns. The findings suggest that the mRNA cocktail developed in this study represents a step forward in ASFV vaccine research and development. This strategy holds promise for contributing to ASFV control by offering possibly safer and more effective alternatives to conventional vaccines. This could significantly impact ASF management and prevention strategies globally, ultimately benefiting animal health and reducing economic losses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.